Table 2 Re-uses cited by policy sources
Published outputs | Title | Type of study | Policy sources | How cited |
|---|---|---|---|---|
Joanna Le Noury et al. 2015 | Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence | Re-analysis | The state of open data. 25 Oct 2016 | In a chapter stating the ethical necessity of open data in medical research, the re-use is cited as a subsequent analysis that debunked the previous results of the study 329 which stated that “Paroxetine is generally well tolerated and effective for major depression in adolescents” |
Merryn Voysey et al. 2017 | The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses | Meta-analysis | World Health Organization. (2018). The immunological basis for immunization series: module 3: tetanus: update 2018. World Health Organization. https://apps.who.int/iris/handle/10665/275340. License: CC BY-NC-SA 3.0 IGO | The re-use was cited in the immunological basis for immunization series: module 3: tetanus: update 2018 from World Health Organization but the exact context in the text was not found |
Joseline Guetsop Zafack et al. 2019 | Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials | Secondary analysis | The National Immunisation Programme in the Netherlands: Surveillance and developments in 2018–2019 | The re-use was cited in the national immunisation programme in the Netherlands for the 2018–2019 period but the exact context was not found in the text |
Mark Corbett et al. 2017 | Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation | Meta-analysis | National Institute for Health Care Excellence (NICE) guidance: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (https://www.nice.org.uk/guidance/ta537/evidence/committee-papers-pdf-4913117821) | The meta-analysis was cited in NICE as a reference regarding the use of a York model and details on its implementation (5 times): a reference regarding resource use estimates for controlled and uncontrolled psoriasis, a reference for psoriasis severity classification according to the York model, a reference for psoriasis evolution without treatment and a reference stating the lack of clinically meaningful difference in bDMARD responses rates for joint disease or psoriasis between 12 to 24 weeks |
G. A. Mospan et al. 2016 | 5-Day versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI) | Secondary analysis | NICE guidance: Urinary tract infection (lower): antimicrobial prescribing (evidence review) | The re-use is cited as an excluded study in the NICE evidence review (non-relevant population) so it did not contribute to the policy source content |
Lauren M. Schwartz et al. 2016 | Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design | Secondary analysis | World Health Organization. (2020). The immunological basis for immunization series: module 21: rotavirus vaccines. World Health Organization. https://apps.who.int/iris/handle/10665/331323. License: CC BY-NC-SA 3.0 IGO | The re-use was cited in the immunological basis for immunization series: module 21: rotavirus vaccines from World Health Organization but the exact context was not found in the text |